bioAffinity Technologies Inc. (BIAF) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, bioAffinity Technologies Inc. (NASDAQ: BIAF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.91 (-3.96% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), BIAF carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ISPC (iSpecimen Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
Per BIAF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001712762), bioAffinity Technologies Inc. generated $6.2M in revenue (-34.2% YoY), -$14.9M in net income, and -$9.4M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While BIAF currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.04) and Max Pain ($3.06) forces dealer call-delta covering toward $84.74.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
bioAffinity Technologies Inc. (BIAF) dropped -3.96% to $2.91, trading at 2% of its 52-week range ($2.66 – $80.7). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Yahoo Finance Australia report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
SAN ANTONIO, October 29, 2026--bioAffinity Technologies will share benefits of CyPath Lung with North Carolina lung cancer patient advocacy and healthcare community at Nov. 5 event.
bioAffinity Technologies CEO Maria Zennes joined Steve Darling from Proactive to discuss the company's noninvasive lung cancer detection technology, reported 200% year-over-year growth in the second quarter, insurance re
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -34.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on BIAF today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for BIAF. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, bioAffinity Technologies Inc. (BIAF) ranks #850 by composite RQD confidence (29/100, grade E) and #962 by equity capitalization ($3.7M). Within this direct 5-issuer industry benchmark cohort, NRC leads on earnings valuation at 44.8x trailing P/E, while NRC leads on capital efficiency and profitability with 21.0% ROIC and — gross margin. NRC currently holds the highest overall quantitative score in the immediate peer group at 67/100 (C+) compared with BIAF at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BIAF
ACTIVE
bioAffinity Technologies Inc. | E | 29/100 | — | — | -35.0% | -3.96% | $3.7M | Benchmark Subject |
| ISPC iSpecimen Inc. | E | 30/100 | — | 11.2% | -35.0% | +4.19% | $2.1M | /ispc-vs-biaf → |
| ONMD OneMedNet Corp (Class A) | E | 26/100 | — | -30.0% | -35.0% | -3.43% | $25.4M | /onmd-vs-biaf → |
| MXCT MaxCyte Inc. | E | 34/100 | — | 96.0% | -27.1% | -8.09% | $164.1M | /mxct-vs-biaf → |
| NRC NRC Health | C+ | 67/100 | 44.8x | — | 21.0% | +1.45% | $527.1M | /nrc-vs-biaf → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), bioAffinity Technologies Inc. (BIAF) reported GAAP revenue of $6.2M (-34.2% vs. FY2024 revenue of $9.4M , and +143.3% cumulative change since FY2023) , GAAP net income of -$14.9M, operating cash flow of -$9.3M, and free cash flow of -$9.4M (-27.9% YoY). On the balance sheet, BIAF closed FY2025 with $11.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $6.2M | -$14.9M | -$9.3M | -$9.4M | $11.0M | — |
| FY2024 (FY) | 2024-12-31 | $9.4M | -$9.0M | -$7.3M | -$7.3M | $6.5M | — |
| FY2023 (FY) | 2023-12-31 | $2.5M | -$7.9M | -$6.0M | -$6.0M | — | — |
As of 2026-11-03, bioAffinity Technologies Inc. (NASDAQ: BIAF) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $2.91 (-3.96% 1D, market cap $3.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Active quantitative signal LIQUIDITY_TAILWIND (BULLISH, conviction undefined/100) notes: undefined.
Within the Health Care sector (Biotechnology: Commercial Physical & Biological Resarch), BIAF carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ISPC (iSpecimen Inc.) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $2.1M) and ONMD (OneMedNet Corp (Class A)) posts a E grade (26/100 RQD, P/E N/A, ROIC -35.0%, cap $25.4M). Among the 5-stock peer group, NRC leads on earnings multiple (44.8x) while NRC leads on capital efficiency (21.0% ROIC).
Per BIAF's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001712762), bioAffinity Technologies Inc. generated $6.2M in revenue (-34.2% YoY), -$14.9M in net income, and -$9.4M in free cash flow against $11.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
BIAF last traded at $2.91 (-3.96% on volume of 47,276 shares), positioning the stock -51.82% below its 50-day simple moving average ($6.04) and -84.74% below its 200-day simple moving average ($19.07). Across its 52-week range of $2.66 to $80.70, BIAF sits at the 0.3% percentile with a 14-day RSI of 34.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($2.55 to $3.27).
Why BIAF Stock dropped -3.96% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
The per the Roarable RQD rating, BIAF receives an RQD Score of 29 and a letter grade of E, with the verdict "Roarable Strong Sell — Forensic Risk / Avoid." Across the five pillars, the Fundamental Cash Engine scores 8 / 20 (ROIC -35%; FCF yield 0%), signaling that the business is not currently generating economic returns or free cash flow. Whale/13F Flow scores 3 / 20 and Insider Conviction scores 3 / 20, indicating weak institutional and insider-side support in the sourced positioning data. Macro Regime Fit scores 7 / 20 with a Beta of 1.0, meaning the rating sees limited macro-regime alignment. Forensic Balance Sheet scores 8 / 20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5), reflecting a weak accounting-quality profile.
For a prospective investor evaluating the stock today, the implication is that the rating framework views the equity primarily as a high-risk, low-quality position. Upside drivers would have to come from outside the reported cash engine, since current economics show negative operating margin (-60%) and negative net margin (-60%). Valuation tradeoffs are difficult to assess because P/E, EPS, and EV/EBITDA are not available in source data, and the market cap of $3.9M sits against a 52-week range of $2.66 - $80.7, a span that underscores extreme price volatility. Any constructive case would need to rest on catalysts rather than on current cash generation.
bioAffinity Technologies Inc. (BIAF) is a NASDAQ-listed issuer classified in the Health Care sector and the Biotechnology: Commercial Physical & Biological Resarch industry. The source data identifies the company's sector, industry, and exchange, but does not describe its specific products, customers, or revenue model. Revenue is reported in the financial data (FY 2025: $6.2M; FY 2024: $9.4M; FY 2023: $2.5M), which indicates the company generates sales, though the sources do not detail how those sales are generated. Recent news headlines reference a lung cancer risk test (a home-collected test) and a product referred to as CyPath Lung, which suggest diagnostic activity, but the source data does not confirm the full product or go-to-market structure.
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $6.2M | $-10.6M | $-14.9M | N/A | $-9.4M | $6.4M | N/A |
| FY 2024 | $9.4M | $-9.0M | $-9.0M | N/A | $-7.3M | $1.1M | N/A |
| FY 2023 | $2.5M | $-8.0M | $-7.9M | N/A | $-6.0M | N/A | N/A |
Per the SEC financials, reported revenue rose to $6.2M in FY 2025 from $9.4M in FY 2024 after being $2.5M in FY 2023, while net losses persisted in each period. Gross margin is 0%, operating margin is -60%, and net margin is -60%, with ROIC at -35% per the market data. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, with Debt/Equity at 0.5. The balance sheet shows FY 2025 cash of $6.4M against FCF of $-9.4M, and debt is not available in source data for any period.
The Butterfly Supply-Chain Graph lists supply_chain as NONE and contains no butterfly links, so upstream suppliers, downstream customers, and cross-company dependencies are not available in source data. The only sector context provided is Health Care / Biotechnology: Commercial Physical & Biological Resarch. The proprietary liquidity signal implies that BIAF's price sensitivity to net liquidity conditions is high (6.00x elasticity per the graph), meaning second-order moves in Fed balance-sheet and Treasury liquidity could amplify price swings in either direction. Investors should watch the financing cadence: a registered direct offering at market price, combined with negative free cash flow, creates a dilution pathway whose magnitude is not quantified in the source data.
Real-time company headlines, analyst actions, and sector developments for bioAffinity Technologies Inc. (BIAF) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance Australia report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Business Wire report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Timothy Sykes report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
StocksToTrade report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
kalkine.ca report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Stock Titan report covering bioAffinity Technologies Inc. (BIAF) market action, institutional positioning, and fundamental catalysts.
Welcome to the BIAF (bioAffinity Technologies Inc.) Roar Pit. Current RQD Composite is 29/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Commercial Physical & Biological Resarch. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on BIAF, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless bioAffinity Technologies Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on BIAF, the market is fixating on short-term headline noise in Biotechnology: Commercial Physical & Biological Resarch and ignoring the balance sheet and cash flow trajectory. At $3.03 (52-wk range $2.66 - $80.70), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).